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Abstract
Carbapenem-resistant Acinetobacter baumannii (CRAB) is an increasingly common nosocomial pathogen. We sought to identify clinical and
microbiological predictors of 14-day mortality among patients with CRAB bacteraemia. This case-control study included all adult patients in
one Israeli hospital with CRAB on blood culture between July 2008 and June 2011. Cases were defined as patients who died within 14 days
of bacteraemia onset and controls as patients who survived over 14 days. Sequence-typing of the blaOXA-51-like gene and REP-PCR identified
CRAB clone groups. Logistic regression was performed to analyze predictors of 14-day all-cause mortality. To correct for differences in
treatment onset, Cox regression was used to examine the effect of receiving an active antibiotic. Eighty-three cases and 89 controls were
included. Six major CRAB clone groups were identified, with 14-day mortality ranging from 17 to 66%. Independent predictors of 14-day
mortality were severity of illness (OR = 1.38 for each 1-point increase in Sequential Organ Failure Assessment (SOFA) score; 95% CI, 1.21,
1.56), independence in activities of daily living (ADL) on admission (OR = 3.40; 95% CI, 1.20, 9.67, for fully dependent vs. independent),
surgery before bacteraemia (OR = 0.25; 95% CI, 0.11, 0.59) and clone group (OR = 7.76; 95% CI, 2.52, 23.85, for the most virulent group
vs. the reference group). In the multivariate Cox model using a propensity score to adjust for SOFA, clone, ADL and surgery, active
antibiotic treatment was protective (HR = 0.30; 95% CI, 0.15, 0.60). Differences in virulence between CRAB clones may partly explain
heterogeneous results in previous studies of mortality following CRAB infection.
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Introduction
Acinetobacter spp. were in the past frequently ignored as
commensals with relatively low virulence. However, A. bau-
mannii’s impressive ability to acquire resistance mechanisms,
survive for prolonged periods in the hospital environment and
cause nosocomial outbreaks has alerted clinicians to the
emergence of a potentially dangerous pathogen [1–3].
Surveillance data collected globally reveal increased resis-
tance among Acinetobacter spp. isolates over the past decade,
with resistance to carbapenems of up to 88% in Europe [4] and
85% in Latin America [5]. Data from our hospital in Israel show
that resistance of A. baumannii to carbapenems increased from
52% in 2009 to 70% in 2012.
Four Acinetobacter genospecies, A. calcoaceticus, A. bauman-
nii, A. pittii and A. nosocomialis, are phenotypically similar and
are referred to as the A. calcoaceticus – A. baumannii complex.
A. calcoaceticus is an environmental species, while the three
latter are clinically relevant. Simple phenotypic tests do not
permit unambiguous identification of these closely related
species and molecular methods are usually needed [1].
A. baumannii can be specifically identified by detection of the
blaOXA-51-like carbapenemase gene intrinsic to this species
[6,7].
Because A. baumannii typically affects critically ill patients
whose prognosis is influenced not only by infection, it is
challenging to determine the true clinical impact of A. baumannii
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infection and CRAB specifically [1,2]. Numerous studies have
investigated risk factors for adverse outcomes, but limitations
such as failure to distinguish between A. baumannii colonization
and infection, failure to adjust for confounders such as severity
of illness and co-morbid conditions, and suboptimal species
identification, make it difficult to draw definitive conclusions
[1].
The aim of the present study was to identify predictors of
14-day mortality among patients with carbapenem-resistant
A. baumannii (CRAB) bacteraemia. We sought to determine
factors associated with patient characteristics, the antibiotic
treatment given and A. baumannii clone type.
Methods
Study setting and participants
This case-control study was performed at Tel-Aviv Sourasky
Medical Center, a 1300-bed tertiary care teaching hospital in
Israel. The sample included all patients aged 18 or older who
had a peripheral blood culture positive for CRAB, and the
isolate was preserved in the laboratory between July 2008 and
June 2011. Only the first bacteraemic episode from each
patient was considered. Cases were defined as patients who
died within 14 days of bacteraemia onset and controls as
patients who survived for more than 14 days. The protocol
was approved by the hospital’s Institutional Review Board.
Data collection
Data from the patients’ medical records and from hospital
computerized databases were recorded. Data collected
included age, sex, admission from home vs. from an institution,
level of independence in activities of daily living (ADL), number
of hospitalizations in the previous year, and known A. bau-
mannii carriage in the previous year. Co-morbidities were
measured according to the Charlson co-morbidity score
(CCS) [8]. The following data were collected regarding the
current hospitalization: diagnosis on admission, time from
admission to bacteraemia onset, number of surgeries, ICU
stay, presence of a central venous catheter, dialysis, source of
infection, antibiotic treatments, and positive blood culture with
a different organism within 2 days of the CRAB blood culture.
Two different scoring systems were used to quantify the
severity of illness in the 48 h before the onset of bacteraemia:
the Sequential Organ Failure Assessment (SOFA) score [9] and
the Pitt Bacteremia Score (PBS) [10].
Definitions
The outcome of interest was death from any cause within
14 days of bacteraemia onset, defined as the date on which the
first blood culture positive for CRAB was obtained. We chose
14-day mortality as the endpoint to allow adequate ascertain-
ment of treatment response. We reasoned that in critically ill
patients, 30-day mortality is too long, as there are many
competing causes of death, and 7 days is too short a time to
witness a response to treatment. An infection was considered
nosocomial if it developed more than 3 days after admission.
Patients were defined as immunosuppressed if they had HIV or
AIDS, were post-transplant, had received chemotherapy
within 6 weeks, had received systemic steroids (equivalent
to or higher than 20 mg of prednisone) for 2 weeks or other
immunosuppressive agents within 2 weeks before hospitaliza-
tion, or had an absolute neutrophil count of <500/lL on
admission. Source of infection was determined based on
guidelines issued by the Centers for Disease Control and
Prevention [11]. If no other source could be identified, the
bacteraemia was defined as primary. An infection was defined
as polymicrobial if another organism was detected by blood
culture within 2 days of the CRAB blood culture. Antibiotic
treatment was defined as active if the laboratory reported that
the isolate was susceptible to the drug given; the dose,
frequency or length of treatment were not considered.
Microbiological methods
Identification of isolates to the level of the A. baumannii
complex was performed using the VITEK 2 automated system
(bioMerieux, Inc., Durham, NC, USA). Susceptibility results
were interpreted according to the Clinical and Laboratory
Standards Institute (CLSI) guidelines [12]. Isolates were
considered carbapenem-resistant if they were non-susceptible
to imipenem or meropenem. Isolates with intermediate
resistance were regarded as resistant.
All isolates were re-grown from storage and were subjected
to PCR for detection of the blaOXA-51-like gene [6]. Detection
of the blaOXA-51-like gene was regarded as a positive identifi-
cation of A. baumannii to the species level.
Single locus amplification and sequence-typing of the
blaOXA-51-like gene has demonstrated concordance with MLST
typing and has the advantage that typing is based on a single
gene [13,14]. Sequencing of the blaOXA-51-like gene was
performed for all isolates. The primer pair 50-CTAATAAT
TGATCTACTCAAG-30 (forward) and 50-CCAGTGGATG
GATGGATAGATTATC -30 (reverse) was used to amplify
the blaOXA-51-like gene [15]. The PCR products were outsour-
ced for sequencing (HyLabs, Rehovot, Israel) and analyzed by
DNAMAN software (Lynnon Corporation, Pointe-Claire,
Quebec, Canada) and BLAST query (NCBI).
In addition, to improve discrimination within blaOXA-51-like
sequence types, we used repetitive extragenic palindromic
PCR (REP-PCR), a fingerprinting method that is based on the
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use of DNA primers corresponding to naturally occurring
interspersed repetitive elements in the bacterial chromosome
[16]. REP-PCR has been used successfully for genotyping of
A. baumannii [17] and CRAB specifically [18]. The primer pair
used was 50-TTTGCGCCGTCATCAGGC-30 (forward) and
50-ACGTCTTATCAGGCCTAC-30 (reverse). REP-PCR
results were analyzed and interpreted using GelCompar II
software (Applied Maths, Sint-Martens-Latem, Belgium). Sim-
ilarity analyses of the DNA fingerprints were performed with
the Pearson product-moment correlation coefficient method
[19]. A clone group was defined when there was >80%
similarity among its members [19].
Statistical analysis
Statistical analysis was performed using Stata version 12.0
(StataCorp, College Station, TX, USA). Univariate analysis was
carried out using Pearson’s chi-square test for categorical
variables and Student’s t-test for continuous variables. Odds
ratios and 95% confidence intervals were calculated by simple
logistic regression. All variables with a p-value ≤0.10 were
considered for the multivariate logistic regression model. The
final model was chosen using forward stepwise selection. The
discrimination of the model was assessed by calculating the area
under the ROC curve. It was difficult to evaluate the effect of
receiving an antibiotic active against CRAB because, among
cases, death often occurred before the onset of treatment.
Therefore, to control for differences in the time between
bacteraemia onset and start of treatment with an antibiotic
active against CRAB, we modelled treatment as a time-depen-
dent variable and performed univariate Cox regression. We
then ran a multivariate Cox model that included treatment plus
a propensity score created from the variables that were
significant in the multivariate logistic regression.
Results
During the 36-month study period there were 323 first-time
episodes of A. baumannii bacteraemia among adults aged 18
and over; 210 (65%) of the A. baumannii blood isolates were
carbapenem-resistant. The overall 14-day mortality rate of
CRAB bacteraemia was 45.2% for the entire cohort. From this
population of 210 patients with CRAB bacteraemia, the study
sample comprised 172 patients who met eligibility criteria.
Eighty-three (48.3%) died within 14 days of bacteraemia onset
and were defined as cases; the remaining 89 were defined as
controls.
Demographic and clinical characteristics of patients are
summarized in Table 1. Cases and controls were similar with
respect to age (mean age, 70.0 years vs. 65.9 years; p 0.15),
sex (56.6% male vs. 53.9% male; p 0.72) and place of residence
before hospitalization. There were more cases who were fully
dependent in ADL (26.5% vs. 14.6%; p 0.02). CCS was higher
for cases than for controls (mean score, 4.44 vs. 3.30; p 0.007).
Among cases there were more patients who were immuno-
suppressed (31.3% vs. 13.5%; p 0.006) or on dialysis (30.1% vs.
15.7%; p 0.026), and fewer patients who had surgery before
bacteraemia (41.0% vs. 66.3%; p 0.001). Length of hospitaliza-
tion prior to bacteraemia ranged from 0 to 156 days. The
mean time from admission to bacteraemia was 22.8 days for
cases and 28.6 days for controls (p 0.13). SOFA score was
higher in cases than in controls (mean score, 7.41 vs. 4.89;
p <0.001). The second measure of severity of index, PBS, was
similar for both groups.
Microbiological findings are summarized in Table 2. There
was no significant difference between cases and controls
regarding source of infection or polymicrobial infections.
TABLE 1. Demographic and clinical characteristics of cases and controls
Cases (n = 83) Controls (n = 89) OR, 95% CI p-value
Male sex, n (%) 47 (56.6) 48 (53.9) 0.90 (0.49, 1.64) 0.72
Age, mean (SD) 70.0 (18.2) 65.9 (19.7) 1.01 (1.00, 1.03) 0.15
Place of residence before hospitalization, n (%)
Home 52 (62.7) 56 (62.9) Reference
Long-term care facility or other hospital 20 (24.1) 23 (25.8) 0.94 (0.46, 1.90) 0.86
Other or unknown 11 (13.3) 10 (11.2) 1.18 (0.46, 3.02) 0.72
ADL on admission, n (%)
Independent 36 (43.4) 55 (61.8) Reference
Requires partial help 17 (20.5) 16 (18.0) 1.62 (0.73, 3.62) 0.24
Fully dependent 22 (26.5) 13 (14.6) 2.59 (1.16, 5.78) 0.02
Unknown 8 (9.6) 5 (5.6) 2.44 (0.74, 8.07) 0.14
Charlson score, mean (SD) 4.44 (2.81) 3.30 (2.55) 1.17 (1.04, 1.32) <0.01
Immunosuppressed, n (%) 26 (31.3) 12 (13.5) 2.93 (1.36, 6.29) <0.01
Known Acinetobacter carriage in past year, n (%) 30 (36.1) 31 (35.2) 1.04 (0.56, 1.95) 0.90
Any previous hospitalization in past year, n (%) 43 (51.8) 37 (41.6) 1.51 (0.83, 2.76) 0.18
Surgery before bacteraemia, n (%) 34 (41.0) 59 (66.3) 0.35 (0.19, 0.66) <0.01
Dialysis before bacteraemia, n (%) 25 (30.1) 14 (15.7) 2.31 (1.10, 4.83) 0.03
Days in hospital before bacteraemia, mean (SD) 22.8 (20.1) 28.6 (27.7) 0.99 (0.98, 1.00) 0.13
Nosocomial infection, n (%) 73 (88.0) 81 (91.0) 0.72 (0.27, 1.92) 0.51
Central venous catheter, n (%) 63 (75.9) 64 (71.9) 1.23 (0.62, 2.44) 0.55
In ICU before bacteraemia, n (%) 44 (53.0) 59 (66.3) 0.57 (0.31, 1.06) 0.08
SOFA score, mean (SD) 7.41 (3.74) 4.89 (2.78) 1.27 (1.14, 1.42) <0.01
Pitt score, mean (SD) 3.58 (2.56) 3.07 (2.33) 1.09 (0.96, 1.23) 0.17
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There was also no significant difference in the time between
sending the culture and obtaining results (3.5 days vs. 3.4 days;
p 0.25). Antibiotic susceptibility patterns of isolates were
similar for cases and controls (Table 3).
Sequence-typing of the blaOXA-51-like gene categorized
CRAB isolates into four major OXA groups (Table 2).
OXA-66 was the dominant group, containing 124 isolates.
REP-PCR further divided this group into three clones (REP1,
REP 2 and ‘other’ REP patterns). There was significant
variation in 14-day mortality between clone groups: mortality
was lowest in clone group OXA-65 (16.7%), and highest in
OXA-66 REP 2 (65.7%) and OXA-71 (63.6%). Compared with
the reference group (OXA-66 REP 1), the odds of dying within
14 days were about four times higher for the OXA-66 REP 2
clone (OR, 4.31; 95% CI, 1.79, 10.33) and the OXA-71 clone
(OR, 3.94; 95% CI, 1.43, 10.87).
Only 34 of the 83 cases (41.0%) received active antibiotic
treatment within 5 days compared with 67 of 89 controls
(75.3%). Twenty-four of 83 cases (28.9%) received active
treatment within 2 days of bacteraemia onset compared with
42 of 89 controls (47.2%). Regarding treatment given within
5 days, colistin was the most frequent antibiotic used.
Twenty-nine cases received colistin; 15 as monotherapy, 11
in combination with a carbapenem, and three in combination
with another active antibiotic. Sixty controls received colistin;
42 as monotherapy, 12 with a carbapenem, five with another
active antibiotic, and one with both a carbapenem and
ampicillin-sulbactam. Other active monotherapy included
amikacin (two cases), gentamicin (one case and one control),
minocycline (one control), tigecycline (one case and two
controls), ampicillin-sulbactam (one control) and trimetho-
prim/sulfamethoxazole (one case and two controls). There
was a significant difference between cases and controls in the
proportion of patients who received active antibiotic treat-
ment within 2 days or within 5 days (p <0.001 for both).
However, these results are confounded because 74% of cases
who did not receive active treatment died before culture
results were available; that is, they did not survive long
enough to get correct treatment. Thus, to determine the
true effect of receiving an active antibiotic, we modelled
treatment as a time-dependent variable and used Cox
regression. In the univariate Cox model, active antibiotic
treatment lowered mortality by 71% (HR = 0.29; 95% CI,
0.14, 0.57).
TABLE 2. Microbiological charac-
teristics of bacteraemia in cases
and controls
Cases (n = 83) Controls (n = 89) OR, 95% CI p-value
Bacteraemia source, n (%)
CLABSIa 37 (44.6) 37 (41.6) Reference
Bacteraemia secondary to infection inb 32 (38.6) 32 (36.0) 1.0 (0.51, 1.95) 0.66
Urine 10 8
Respiratory tract 17 17
Wound 3 5
Biliary tract 2 2
Primary bacteraemia, % 14 (16.9) 20 (22.5) 0.70 (0.31, 1.59)
Polymicrobialc, n (%) 23 (27.7) 30 (33.7) 0.75 (0.39, 1.45) 0.40
Clone group, n (%)
OXA 66, REP 1 20 (24.1) 45 (50.6) Reference
OXA 66, REP 2 23 (27.7) 12 (13.5) 4.31 (1.79,10.33) <0.01
OXA 66, REP other 12 (14.5) 12 (13.5) 2.25 (0.86, 5.86) 0.01
OXA 71 14 (16.9) 8 (9.0) 3.94 (1.43, 10.87) <0.01
OXA 65 1 (1.2) 5 (5.6) 0.45 (0.049, 4.10) 0.48
Other (OXA 69,70, 248 or undefined) 13 (15.7) 7 (7.9) 4.18 (1.44, 12.05) <0.01
Days from culture to results, mean (SD) 3.53 (0.89) 3.38 (0.79) 1.24 (0.86, 1.78) 0.25
aCLABSI, central line-associated blood stream infection.
bBacteraemia was defined as secondary if it occurred ≤3 days before or ≤7 days after Acinetobacter infection at another
site.
cPolymicrobial was defined as other organisms isolated on blood culture within 2 days of Acinetobacter bacteraemia.
TABLE 3. Antibiogram of carbape-
nem-resistant A. baumannii blood
cultures of cases and controls. There
was no significant difference in sen-
sitivity between cases and controls
for any drug.
Cases (n = 83) Controls (n = 89)
No. samples
tested
No. samples
sensitive
%
sensitive
No. samples
tested
No. samples
sensitive
%
sensitive
Ampicillin/sulbactam 83 32 38.6 89 28 31.5
Colistin 81 81 100 89 89 100
Gentamicin 83 13 15.7 89 9 10.1
Amikacin 76 34 44.7 81 44 54.3
Tobramycin 74 22 29.7 83 26 31.3
Levofloxacin 83 1 1.2 89 2 2.2
Minocycline 81 27 33.3 88 30 34.1
Tigecycline 75 46 61.3 82 52 63.4
Trimethoprim/
sulfamethoxazole
83 30 36.1 89 30 33.7
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Multivariate analysis results are presented in Table 4.
Independent predictors of 14-day mortality were SOFA score,
clone group, ADL category on admission and surgery having
surgery before the onset of bacteraemia. Area under the ROC
curve was 0.84. In the multivariate Cox model that included
treatment plus a propensity score created from the variables
SOFA score, clone group, ADL category and surgery, active
treatment had a significant protective effect (HR = 0.30; 95%
CI, 0.15, 0.60).
To examine whether our results were confounded by
deaths in patients with polymicrobial infections, we re-ran the
multivariate models including only patients with monomicro-
bial infections. The results were similar to the original models.
Discussion
A. baumannii is an emerging nosocomial pathogen that causes
serious infections in hospitalized patients. Crude mortality
from A. baumannii bacteraemia ranges widely from 30 to 52%,
which is comparable to other Gram-negative bacteria [20,21].
In a systematic review of studies reporting in-hospital mortality
among patients infected with A. baumannii, the attributable
mortality ranged from 7.8 to 43% and differed significantly
between general wards and the ICU [22]. These inconsistent
findings may be explained by significant methodological
differences between studies [1], different patient populations
and inappropriate antibiotic treatment, as well as differences in
virulence of Acinetobacter spp. [22].
In order to distinguish between A. baumannii colonization
and infection, we recruited only patients with positive
peripheral blood cultures. Furthermore, we employed a
molecular assay to identify A. baumannii to the species level.
Controlling for co-morbid conditions and severity of illness
(SOI) is important in identifying independent predictors of
outcome [23]. SOI 48 h before onset of bacteraemia was
assessed with the SOFA scoring system. In a study of
A. baumannii bacteraemia, SOFA score was a predictor of
14-day mortality and was highly correlated with the Acute
Physiology and Chronic Health Evaluation (APACHE) II scoring
system [24]. Our study concurs with these results. We found
that patients who had surgery before the onset of bacteraemia
had lower 14-day mortality. We believe that this association is
explained by differences in patient populations rather than a
true protective effect of surgery.
Our study included only patients with CRAB. Carbapenem
resistance may increase mortality by delaying the onset of
effective antimicrobial treatment. In a Korean study, 30-day
mortality among patients with imipenem non-susceptible
Acinetobacter spp. bacteraemia increased from 28.6 to 73.1%
if inappropriate therapy was given [25]. However, another
study conducted in Korea found no significant difference in
mortality between patients with multidrug-resistant Acineto-
bacter spp. bacteraemia who received colistin (the only
effective agent) and those who did not [26]. Inconsistent
findings regarding the impact of treatment may also be due to
high failure rates with colistin monotherapy [27].
In our study, 60% of cases did not receive an active
antibiotic within 5 days of bacteraemia onset; however, this
was mainly because a large proportion of cases died before
culture results were available. Thus, to correct for differ-
ences in timing of administration of an antibiotic active
against CRAB, we used Cox regression. Antibiotic treatment
was significantly associated with lower 14-day mortality after
adjusting for a propensity score created from the variables
SOFA score, clone group, ADL category and surgery.
Our finding that active treatment has a significant protective
effect suggests that even though agents to treat CRAB are
believed to be suboptimal, they still have an important
influence on survival. This should be considered when
choosing empirical antibiotic therapy in units with a high
incidence of CRAB.
Our study is unique in including clonality evaluation in the
analysis of factors associated with mortality. We found a
significant difference between clones with respect to 14-day
mortality (16.7–65.7%); clone group was an independent
predictor of 14-day mortality. A. baumannii is well known for
its genetic plasticity, acquiring genes related to resistance and
pathogenesis [28,29]. We believe that our findings point to
differences in virulence between various clones that may be
related to different acquisition or expression of virulence
genes. Further research is needed to define the molecular
mechanisms involved in the virulence of these clones. Differ-
ences in virulence may provide further explanation for the
heterogeneity between study results regarding mortality due
TABLE 4. Multivariate logistic regression model of predic-
tors of 14-day mortality in patients with A. baumannii bacter-
aemiaa
Variable OR, 95% CI p-value
ADL on admission
Independent Reference
Requires partial help 1.91 (0.68, 5.39) 0.22
Fully dependent 3.40 (1.20, 9.67) 0.02
Unknown 6.33 (1.42, 28.19) 0.02
SOFA score 1.38 (1.21, 1.56) <0.01
Clone group
OXA 66, REP 1 Reference
OXA 66, REP 2 7.76 (2.52, 23.85) <0.01
OXA 66, REP other 3.95 (1.17, 13.26) 0.03
OXA 71 5.61 (1.71, 18.38) <0.01
OXA 65 0.68 (0.61, 7.58) 0.76
Other (OXA 69,70, 248 or undefined) 6.70 (1.85, 24.22) <0.01
Surgery before bacteraemia 0.25 (0.11, 0.59) <0.01
aTreatment was not included in this model.
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to CRAB infections, as different clones are endemic in different
regions and at different times [30].
Our study had several limitations. First, because data were
collected retrospectively from medical records, some param-
eters of SOI scoring had to be inferred from the charts.
Mortality was defined as all-cause mortality and not sep-
sis-related mortality because it was not always possible to
determine the exact cause of death from the medical records.
However, because our outcome was death within 14 days of
bacteraemia, we believe that infection was a contributing
factor of mortality, if not the terminal event, in almost all cases.
Our study was strengthened by the inclusion of a large
number of patients, molecular species identification, adjust-
ment for severity of illness and the use of a time-dependent
analysis to examine the effect of antibiotic treatment.
In conclusion, we found that the prognosis of patients with
CRAB bacteraemia is determined by all three factors: patient
characteristics, specifically ADL category and severity of
underlying illness, infection with a specific bacterial clone and
receiving active antibiotic treatment.
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